{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:03:57Z","timestamp":1791540237542,"version":"4.3.4"},"reference-count":115,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00400","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T06:38:58Z","timestamp":1498199938000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Frontiers in Drug Research and Development for Inflammatory Bowel Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Diego","family":"Curr\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1111\/bph.13353","article-title":"The concise guide to PHARMACOLOGY 2015\/16: catalytic receptors.","volume":"172","author":"Alexander","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.","volume":"4","author":"Allez","year":"2010","journal-title":"J. Crohns Colitis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bpg.2014.05.001","article-title":"Treatment algorithms in Crohn\u2019s - up, down or something else?","volume":"28","author":"Antunes","year":"2014","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects.","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease.","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/ajg.2012.301","article-title":"Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing.","volume":"107","author":"Bessissow","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1479-7364-5-1-30","article-title":"Evolutionary divergence and functions of the human interleukin (IL) gene family.","volume":"5","author":"Brocker","year":"2010","journal-title":"Hum. Genomics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1021\/ml500389m","article-title":"Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor.","volume":"5","author":"Buzard","year":"2014","journal-title":"ACS Med. Chem. Lett"},{"key":"B9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.01405.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"B10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/pr.110.003111","article-title":"International Union of Basic and Clinical Pharmacology. LXXVIII. lysophospholipid receptor Nomenclature.","volume":"62","author":"Chun","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1093\/ecco-jcc\/jjw019.014","article-title":"Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn\u2019s disease who are anti tumor necrosis factor inadequate responders.","volume":"10","author":"Danese","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"B13","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.4049\/jimmunol.178.4.2458","article-title":"FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells.","volume":"178","author":"Daniel","year":"","journal-title":"J. Immunol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1016\/j.molimm.2007.02.026","article-title":"FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions.","volume":"44","author":"Daniel","year":"","journal-title":"Mol. Immunol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-015-0465-x","article-title":"Update on the medical management of crohn\u2019s disease.","volume":"17","author":"Deepak","year":"2015","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.2147\/DDDT.S102141","article-title":"Ustekinumab in treatment of Crohn\u2019s disease: design, development, and potential place in therapy.","volume":"10","author":"Deepak","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3892\/or.16.4.699","article-title":"The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.","volume":"16","author":"Deguchi","year":"2006","journal-title":"Oncol. Rep."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(16)30699-0","article-title":"856 efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe crohn\u2019s disease: results of a phase 2B randomized placebo-controlled trial.","volume":"150","author":"D\u2019Haens","year":"2016","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"B20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis.","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for crohn\u2019s disease.","volume":"375","author":"Feagan","year":"","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Efficacy and safety of induction therapy with the selective IL-23 inhibitor BI 655066 in patients with moderate-to-severe crohn\u2019s disease: results of a randomized, double-blind, placebo-controlled phase II study.","volume":"150","author":"Feagan","year":"","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Efficacy and safety of re-induction treatment with selective IL-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease.","volume":"4","author":"Feagan","year":"","journal-title":"Unit. Eur. Gastroenterol. J."},{"key":"B24","article-title":"Safety, pharmacokinetics, and pharmacodynamics of a human anti-IL-6 monoclonal antibody PF-04236921 in healthy subjects.","volume":"71","author":"Fogel","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"G267","DOI":"10.1152\/ajpgi.00496.2005","article-title":"FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis.","volume":"291","author":"Fujii","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1002\/eji.200838359","article-title":"FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow.","volume":"38","author":"Fujii","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690550).","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.crohns.2009.03.001","article-title":"CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-\u03b1 and MMP-3 production in patients with inflammatory bowel disease.","volume":"3","author":"Gordon","year":"2009","journal-title":"J. Crohns Colitis"},{"key":"B29","article-title":"A phase 1 study to estimate the absolute oral bioavailability of tofacitinib (CP-690550) in healthy subjects.","volume":"51","author":"Gupta","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bcp.13203","article-title":"Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.","volume":"83","author":"Harada","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022053","article-title":"Signaling receptors for TGF-\u03b2 family members.","volume":"8","author":"Heldin","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.coi.2016.10.001","article-title":"Targeting cytokine signaling in autoimmunity: back to the future and beyond.","volume":"43","author":"Hirahara","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/17425255.2016.1196188","article-title":"Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators.","volume":"12","author":"Juif","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity.","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/mi.2016.35","article-title":"Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease.","volume":"10","author":"Karuppuchamy","year":"2017","journal-title":"Mucosal Immunol."},{"key":"B36","article-title":"Methods for producing phenylalanine derivatives having a quinazolinedione skeleton and intermediates for production thereof.","author":"Kataoka","year":"2012"},{"key":"B37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis.","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.advms.2016.09.001","article-title":"Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease.","volume":"62","author":"Kmie\u0107","year":"2017","journal-title":"Adv. Med. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/cpdd.171","article-title":"Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.","volume":"4","author":"Krishnaswami","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/bph.12904","article-title":"Preclinical development of AMG 139 a human antibody specifically targeting IL-23.","volume":"172","author":"K\u00f6ck","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jcph.178","article-title":"Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease.","volume":"54","author":"Krishnaswami","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.","volume":"136","author":"Krueger","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.115","article-title":"Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator.","volume":"11","author":"K\u00fchbacher","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cpdd.143","article-title":"The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.","volume":"3","author":"Lawendy","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.114","article-title":"Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator.","volume":"11","author":"Lee","year":"2017","journal-title":"J. Crohns Colitis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrd.2015.10","article-title":"Integrin-based therapeutics: biological basis, clinical use and new drugs.","volume":"15","author":"Ley","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease.","volume":"510","author":"Maceyka","year":"2014","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(09)62956-562956-5","article-title":"Mechanistic population pharmacokinetics (PK) model of PF-00547659 a fully human IgG2 Anti-MAdCAM antibody, in ulcerative colitis patients: results of a first in human (Fih) study.","volume":"136","author":"Martin","year":"2009","journal-title":"Gastroenterology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3434","article-title":"TGF\u03b2 signaling in context.","volume":"13","author":"Massagu\u00e9","year":"2012","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690550 in rat adjuvant-induced arthritis.","volume":"7","author":"Meyer","year":"2010","journal-title":"J. Inflamm. (Lond.)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-12-51","article-title":"Inhibitory effects of the JAK inhibitor CP690550 on human CD4(+) T lymphocyte cytokine production.","volume":"12","author":"Migita","year":"2011","journal-title":"BMC Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.11.008","article-title":"Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease.","volume":"147","author":"Mitroulis","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/mt.2011.290","article-title":"Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn\u2019s disease.","volume":"20","author":"Monteleone","year":"2012","journal-title":"Mol. Ther."},{"key":"B54","first-page":"1","article-title":"Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease.","volume":"8","author":"Monteleone","year":"2001","journal-title":"J. Clin. Invest."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease.","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1021\/bi401596q","article-title":"Integrin cytoplasmic tail interactions.","volume":"53","author":"Morse","year":"2014","journal-title":"Biochemistry"},{"key":"B57","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection.","volume":"54","author":"Namour","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.4049\/jimmunol.1301843","article-title":"TGF-\u03b2: guardian of T cell function.","volume":"191","author":"Oh","year":"2013","journal-title":"J. Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer.","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention.","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/bph.12134","article-title":"Pharmacology of AMG 181 a human anti-\u03b14\u03b27 antibody that specifically alters trafficking of gut-homing T cells.","volume":"169","author":"Pan","year":"","journal-title":"Br. J. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/bcp.12418","article-title":"Clinical pharmacology of AMG 181 a gut-specific human anti-\u03b14\u03b27 monoclonal antibody, for treating inflammatory bowel diseases.","volume":"78","author":"Pan","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12904","article-title":"Clinical pharmacology, safety, and effects of anti-IL-23 antibody AMG 139.","volume":"1","author":"Pan","year":"","journal-title":"Unit. Eur. Gastroenterol. J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Efficacy and safety of tofacitinib for oral induction therapy in patients with moderate to severe crohn\u2019s disease: results of a phase 2B randomized placebo-controlled trial.","volume":"150","author":"Pan\u00e9s","year":"2016","journal-title":"Gastroenterology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1093\/ecco-jcc\/jjx002.494","article-title":"Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers.","volume":"11","author":"Peyrin-Biroulet","year":"","journal-title":"J. Crohns Colitis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/ecco-jcc\/jjx002.010","article-title":"Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study.","volume":"11","author":"Peyrin-Biroulet","year":"","journal-title":"J. Crohns Colitis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1172\/JCI76369","article-title":"Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.","volume":"125","author":"Proia","year":"2015","journal-title":"J. Clin. Invest."},{"key":"B68","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1476-5381.2009.00137.x","article-title":"Pharmacological characterization of PF-00547659 an anti-human MAdCAM monoclonal antibody.","volume":"157","author":"Pullen","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jbior.2015.09.001","article-title":"Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation.","volume":"60","author":"Pyne","year":"2016","journal-title":"Adv. Biol. Regul."},{"key":"B70","first-page":"S285","article-title":"A multicentre, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of the S1P receptor modulator KRP203 in subjects with moderately active refractory ulcerative colitis.","volume":"10","author":"Radeke","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s10620-011-1628-8","article-title":"Pharmacologic evaluation of sulfasalazine, FTY720 and anti-IL-12\/23p40 in a TNBS-induced Crohn\u2019s disease model.","volume":"56","author":"Radi","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)34075-0","article-title":"A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis: results of the TURANDOT study.","volume":"148","author":"Reinisch","year":"2015","journal-title":"Gastroenterology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A randomised phase I study of etrolizumab (rhuMAb \u03b27) in moderate to severe ulcerative colitis.","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"key":"B75","first-page":"438","article-title":"The present and future of inflammatory bowel disease treatment.","volume":"12","author":"Sandborn","year":"2016","journal-title":"Gastroenterol. Hepatol. (N. Y.)."},{"key":"B76","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1093\/ecco-jcc\/jjx002.034","article-title":"Efficacy and safety of abrilumab (AMG 181\/MEDI 7183) therapy for moderate to severe Crohn\u2019s disease.","volume":"11","author":"Sandborn","year":"","journal-title":"J. Crohns Colitis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1093\/ecco-jcc\/jjx002.033","article-title":"Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study.","volume":"11","author":"Sandborn","year":"","journal-title":"J. Crohns Colitis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.013","article-title":"Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension.","volume":"11","author":"Sandborn","year":"","journal-title":"J. Crohns Colitis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1093\/ecco-jcc\/jjw019.081","article-title":"Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomized, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate to severe ulcerative colitis.","volume":"10","author":"Sandborn","year":"","journal-title":"J. Crohns Colitis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease.","volume":"69","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis.","volume":"374","author":"Sandborn","year":"","journal-title":"N. Engl. J. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.crohns.2014.02.021","article-title":"Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases.","volume":"8","author":"Sandborn","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"B83","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(15)30542-4","article-title":"Anti-MAdCAM-1 antibody (PF-00547659) for active refractory crohn\u2019s disease: results of the OPERA study.","volume":"148","author":"Sandborn","year":"2015","journal-title":"Gastroenterology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1093\/ecco-jcc\/jjx002.031","article-title":"Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial.","volume":"11","author":"Sandborn","year":"","journal-title":"J. Crohns Colitis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(16)30622-9","article-title":"Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials.","volume":"150","author":"Sandborn","year":"","journal-title":"Gastroenterology"},{"key":"B86","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjx002.113","article-title":"A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinib, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis.","volume":"11","author":"Sands","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B87","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1093\/ecco-jcc\/jju027.025","article-title":"A randomized, double-blind placebo-controlled phase 2a induction study of MEDI2070 (anti-p19 antibody) in patients with active e Crohn\u2019s disease who have failed anti-TNF antibody therapy.","volume":"9","author":"Sands","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1042\/CS20110086","article-title":"TGF-\u03b2\/TGF-\u03b2 receptor system and its role in physiological and pathological conditions.","volume":"121","author":"Santiba\u00f1ez","year":"2011","journal-title":"Clin. Sci. (Lond.)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell. Signal."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity.","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can. J. Gastroenterol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","article-title":"American college of rheumatology guideline for the treatment of rheumatoid arthritis.","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw163","article-title":"The complexity of alpha E beta 7 blockade in inflammatory bowel diseases.","author":"Smids","year":"2016","journal-title":"J. Crohns Colitis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1124\/mol.114.097261","article-title":"FTY720 phosphate activates sphingosine-1-phosphate receptor 2 and selectively couples to G\u03b112\/13\/Rho\/ROCK to induce myofibroblast contraction.","volume":"87","author":"Sobel","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1111\/j.1476-5381.2011.01205.x","article-title":"A humanized monoclonal antibody targeting the \u03b27 integrin selectively blocks intestinal homing of T lymphocytes.","volume":"16","author":"Stefanich","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/bph.13641","article-title":"Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.","volume":"174","author":"Sugahara","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.crohns.2013.03.014","article-title":"Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis in mice.","volume":"7","author":"Sugiura","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(09)60816-7","article-title":"Oral alpha-4 integrin inhibitor (AJM300) in patients with active crohn\u2019s disease \u2014 a randomized, double-blind, placebo-controlled trial.","author":"Takazoe","year":"2009","journal-title":"Gastroenterology"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis.","author":"Ungaro","year":"2016","journal-title":"Lancet"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-015-0025-y","article-title":"Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.","volume":"15","author":"Valenzuela","year":"2015","journal-title":"BMC Dermatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634 a selective inhibitor of JAK1 for the treatment of inflammatory diseases.","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J. Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1002\/eji.201344428","article-title":"Adaptor regulation of LFA-1 signaling in T lymphocyte migration: potential druggable targets for immunotherapies?","volume":"44","author":"Verma","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"B104","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2 double-blind, randomised, placebo-controlled trial.","volume":"389","author":"Vermeire","year":"","journal-title":"Lancet"},{"key":"B105","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1093\/ecco-jcc\/jjx002.022","article-title":"Maintenance of clinical effect in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study.","volume":"11","author":"Vermeire","year":"","journal-title":"J. Crohns Colitis"},{"key":"B106","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers.","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"key":"B107","article-title":"Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon of active Crohn\u2019s disease patients.","volume":"4","author":"Visvanathan","year":"2016","journal-title":"Unit. Eur. Gastroenterol. J."},{"key":"B108","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/med.21402","article-title":"Therapeutic strategies and pharmacological tools influencing S1P signaling and metabolism.","volume":"37","author":"Vogt","year":"2017","journal-title":"Med. Res. Rev."},{"key":"B109","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bph.13654","article-title":"Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation.","volume":"174","author":"Wang","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1093\/ecco-jcc\/jju027.069027.069","article-title":"Etrolizumab population pharmacokinetics (Pop PK) and covariate analysis in patients with moderately to severely active ulcerative colitis (UC).","volume":"9","author":"Wei","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"B111","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).","volume":"76","author":"Westhovens","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B112","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J. Rheumatol."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"AJM300 study group. safety and efficacy of AJM300 oral antagonist of \u03b14 integrin, in induction therapy for patients with active ulcerative colitis.","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"B114","first-page":"S19","article-title":"Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing.","volume":"33","author":"Zundler","year":"2015","journal-title":"Clin. Exp. Rheumatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4010005","article-title":"Integrating immunologic signaling networks: the JAK\/STAT pathway in colitis and colitis-associated cancer.","volume":"4","author":"Zundler","year":"2016","journal-title":"Vaccines"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T06:39:05Z","timestamp":1498199945000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,23]]},"references-count":115,"alternative-id":["10.3389\/fphar.2017.00400"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00400","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,23]]},"article-number":"400"}}